Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention

Sherman, Brian J.; Baker, Nathaniel L.; McRae‐Clark, Aimee L.

doi:10.1016/j.psychres.2017.01.027

Cited by 30 publications

(14 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cutoffs were not specified in five trials (Babor et al, 2004;Levin et al, 2011;Hoch et al, 2014Hoch et al, , 2012Stephens et al, 1994). Only five trials used biological matrices other than urinalysis; three pharmacological trials (two inpatient) used blood plasma to quantify THC and cannabinoid metabolite concentrations (Allsop et al, 2014;Johnston et al, 2014;Trigo et al, 2018), and two used hair (Barrowclough et al, 2014) or saliva (Sherman et al, 2017) to confirm self-reported cannabis use during and after treatment.…”

Section: Cannabis Use Measuresmentioning

confidence: 99%

“…Post-TX: prior to each follow-up CAT 2 (0) 0 Bonsack et al, 2011;Roffman et al, 1988 Total: 32 2018 ( Allsop et al, 2014;Carpenter et al, 2009;Johnston et al, 2014;Mason et al, 2012;McRae-Clark et al, 2016;Miranda et al, 2017;Sherman et al, 2017;Trigo et al, 2018 2 Joints/cones Bonsack et al, 2011;Gates et al, 2012;Hendriks et al, 2011;Jungerman et al, 2007;Kadden et al, 2007;MTPRG, 2004Brunette et al, 2011Levin et al, 2004 3 Standard cannabis units (defined as 3 cones OR a joint containing 0. (1) Hill et al, 2017;Johnston et al, 2014;Levin et al, 2004Levin et al, , 2013…”

Section: Supplementary Materialsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder

Lee

Schlienz

Peters

et al. 2019

Drug and Alcohol Dependence

View full text Add to dashboard Cite

Cannabis use disorder (CUD) is prevalent and demand for treatment is increasing, yet few individuals engage in formal treatment and the efficacy of established interventions for CUD is modest. Existing clinical trials evaluating psychosocial and pharmacological treatments for CUD have incorporated a wide variety of measures for assessing cannabis use outcomes, including abstinence, self-reported frequency and quantity used, withdrawal, use/dependence severity, and other psychosocial outcomes. The heterogeneity of measures and outcomes has limited quantitative analyses of the comparative effectiveness of existing interventions. The purpose of this systematic review is to: 1) identify and characterize approaches for measuring cannabis use in existing CUD intervention trials, including abstinence, frequency and quantity of use, and 2) summarize measures used to assess treatment efficacy in other outcome domains (e.g., cannabis use severity, psychosocial functioning, cannabis withdrawal), and provide a platform for future research to evaluate which outcome measures are most likely to reflect treatment efficacy and clinically significant improvement in other outcome domains.

show abstract

Section: Cannabis Use Measuresmentioning

confidence: 99%

Section: Supplementary Materialsmentioning

confidence: 99%

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder

Lee

Schlienz

Peters

et al. 2019

Drug and Alcohol Dependence

View full text Add to dashboard Cite

show abstract

“…There is some evidence from two small pilot studies in cannabis users that i.n. OXT may be effective at (1) reducing self-reported cannabis use in cannabis-dependent individuals (Sherman et al, 2017), and (2) decreasing stress-induced cannabis craving and dehydroepiandrosterone (DHEA; a stress-related hormone) levels (McRae-Clark et al, 2013). Unfortunately these studies did not examine sex differences even though OXT is sexually dimorphic at the anatomical, neurochemical and behavioral levels (see reviews by Bisagno & Cadet, 2014; MacDonald & Feifel, 2013; Neumann & Slattery, 2016).…”

Section: Introductionmentioning

confidence: 99%

Sex differences in stress reactivity after intranasal oxytocin in recreational cannabis users

Reed

Haney

Manubay

et al. 2019

Pharmacology Biochemistry and Behavior

View full text Add to dashboard Cite

Cannabis is the most widely used illicit drugs and the changing legal, political and cultural climate will likely increase cannabis use further. One factor that may underlie the transition from recreational use to problematic use is stress. The hormone oxytocin (OXT) modulates stress and may have therapeutic efficacy for substance use disorders, but few studies have examined OXT in cannabis users. Another factor is sex; although more men smoke cannabis, the transition from recreational to problematic use is faster in women. Using a within-subjects design, the effects of intranasal (i.n.) oxytocin (OXT; 40 IU) administration on stress reactivity (using the Trier Social Stress Test; TSST) and cannabis (5.6% THC) self-administration was assessed in recreational cannabis using men (n=31) and women (n=32) relative to i.n. placebo (PBO) and no-stress (NST) conditions. The TSST produced expected subjective and cardiovascular effects compared to the NST. However, in the i.n. OXT-TSST condition, positive subjective effects were lower and negative subjective effects were higher in women compared to PBO administration and compared to men. Further, latency to self-administer cannabis was longer in women than men and women self-administered less cannabis than men regardless of stress condition. There were no differences in cannabis craving as a function of sex, stress, or medication. These results suggest that OXT administration may lead to greater stress reactivity in recreational cannabis users, particularly women, and support growing evidence that sex differences should be carefully considered when examining the therapeutic potential of OXT.

show abstract

“…A recent small placebo-controlled pilot by Sherman et al (2017) explored the role of oxytocin in enhancing psychosocial treatment for CUD. Oxytocin is a hypothalamic neuropeptide that has a critical role in social cognition and behavior.…”

Section: Oxytocinmentioning

confidence: 99%

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal

Brezing

Levin

2017

Neuropsychopharmacol.

114

View full text Add to dashboard Cite

Cannabis use disorder (CUD) commonly occurs and carries a notable economic and functional burden at both individual and societal levels. While there are no clearly efficacious medication treatments for CUD, 20 years of committed and high-quality research in the human laboratory and clinical settings have resulted in medications with demonstrated effectiveness in the treatment of cannabis withdrawal, the ability to reduce cannabis use, and results that point to promising future work. The current state of pharmacology research for CUD highlights the need to consider particular characteristics of patients, such as gender, impulsivity, and severity of cannabis use, when selecting a medication in the off-label treatment of CUD or cannabis withdrawal. As a field, the body of work also exposes some areas in need of improvement in study design, selection of outcome measures, interpretation of results, and the overall process of evaluating candidate medications. Coming to a consensus as a field and addressing these gaps in future research will likely lend itself to further advances in improving the lives of patients with CUD.

show abstract

Effect of oxytocin pretreatment on cannabis outcomes in a brief motivational intervention

Cited by 30 publications

References 19 publications

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder

Sex differences in stress reactivity after intranasal oxytocin in recreational cannabis users

The Current State of Pharmacological Treatments for Cannabis Use Disorder and Withdrawal

Contact Info

Product

Resources

About